

From ICUF Newsletter (October, 2011)

NSU Receives Two Patents

Making new discoveries has been the fabric of Nova Southeastern University's Rumbaugh-Goodwin Institute for Cancer Research since its inception in 1959. The latest findings, made by executive director Appu Rathinavelu, Ph.D., are two anti-cancer medications.

Rathinavelu, who is also an associate dean for institutional planning and development at NSU's College of Pharmacy, received two U.S. patents this spring for his medications, code named JFD and F16. JFD is an anti-angiogenic drug that inhibits blood vessels that supply oxygen and nutrients through blood circulation to cancer tissues. Cancer treatment using this drug will eventually shrink and starve cancer tissues. F16 is similar to JFD, but is a lot more potent against breast cancer. Overall, the two drugs are designed to battle breast, ovarian, prostate, lung, and colorectal cancers. "These discoveries could be a potential breakthrough in the fight against these cancers," Rathinavelu said. "Cancer is a modern epidemic that has taken far too many lives. It's time for us to reverse the trend."



Dr. Appu Rathinavelu